• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Anavex Highlights Shared Biology in Autism and Alzheimer

    GLOBENEWSWIRE

    Anavex to Present at 25th Annual Needham Healthcare Conference

    GLOBENEWSWIRE

    Anavex Life Sciences Provides Comprehensive Regulatory Update

    GLOBENEWSWIRE

    Anavex Life Sciences Updates EU Regulatory Review

    GLOBENEWSWIRE

    Anavex Life Presents New Data from its AD-004 Phase IIb/III Trial

    GLOBENEWSWIRE

    Anavex Shows Blarcamesine Effects In PD Model At ADPD 2026

    GLOBENEWSWIRE

    Anavex Presents at 46th TD Cowen Healthcare Conference

    GLOBENEWSWIRE

    Anavex Life Sciences Unveils Q1 2026 Financials And Business

    GLOBENEWSWIRE

    Anavex Life Sciences Names Senior VP Global Head Of Neurology

    GLOBENEWSWIRE

    Anavex Life Sciences Gets FDA Input On Alzheimer`s Program

    GLOBENEWSWIRE

    Anavex Seeks EMA Re-Examination of Blarcamesine Ruling

    GLOBENEWSWIRE

    Anavex Presents Blarcamesine Data at 18th CTAD Conference

    GLOBENEWSWIRE

    Anavex Life Sciences Reveals Fiscal Q4 2025 Finances & Business

    GLOBENEWSWIRE

    Anavex Oral Blarcamesine Shows Ongoing Benefit in Alzheimer

    GLOBENEWSWIRE

    Anavex Life Develops Once-Daily Oral Tablet for ANAVEX 3-71

    GLOBENEWSWIRE

    Anavex Life Sciences Reports Positive Phase 2 Results

    GLOBENEWSWIRE

    Anavex Publishes Blarcamesine Ph IIb/III Alzheimer’s Results

    GLOBENEWSWIRE

    Anavex`s Blarcamesine Prevents Alzheimer’s in Animal Study

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    GLOBENEWSWIRE

    Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    GLOBENEWSWIRE

    Anavex Initiates Regulatory Submission of Blarcamesine for Alzheimers Disease

    GLOBENEWSWIRE

    Anavex`s Phase 2b/3 Trial of Blarcamesine Shows Robust Clinical Efficacy

    GLOBENEWSWIRE

    ANAVEX®2-73 Receives Compassionate Use for Pediatric Patients

    GLOBENEWSWIRE

    Anavex Announces Exceeding of Enrollment Target for the ANAVEX 2-73 EXCELLENCE Phase 2/3 Trial

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.